We are in a new era of cancer therapies and are witnessing the rapid approval of antibodies and small molecule agents that inhibit cancer-associated pathways. We are witnessing the approval of the first vaccine (sipuleucel-T) for the treatment of prostate cancer, and the first immune check point inhibitor (ipilimumab) that blocks the down-regulatory signal, CTLA-4 on T cells, approved for the treatment of malignant melanoma. These groundbreaking examples have opened the floodgates for a whole new class of anticancer agents that harness the power of the immune system to eradicate existing cancer.
展开▼
